Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Abstract Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing
90-day money-back
since the 1970s
A 2015 study by Huang and colleagues in Drug Design, Development and Therapy used a rat alkali-burn model (n=10 per group) and HUVECs treated with BPC-157 at 200800 ng/mL, reporting accelerated wound closure with enhanced granulation tissue, reepithelialization, and dermal remodeling by day 18, alongside increased endothelial migration and vascular tube formation in vitro via ERK1/2 phosphorylation though the abstract does not report numeric % wound closure or p-values
Longer-term data with GLP-1RAs include results from a phase III, 56-week study of liraglutide 3.0 mg vs
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
